Loading company…
MapLight Therapeutics develops drugs and research platforms for neurological and psychiatric disorders.
Founded in 2018, MapLight Therapeutics is based in Burlington, US, and develops treatments for conditions including autism, Parkinson's disease, schizophrenia and Alzheimer's disease psychosis. Its research platforms include optogenetics, transcriptomics and STARmap, and its pipeline includes ML-004, ML-007C-MA, ML-007 and ML-009. In July 2025, it raised USD 372.5 million in Series D funding co-led by Goldman Sachs XIG and Fobion, with participation from Sanofi Ventures, T. Rowe Price Investment Management, Avego, Novo Holdings, 5AM Ventures, Blue Owl and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in